Stay up-to-date with the Divis Labs Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a prominent stock. Explore the latest information on Divis Labs, including: ...

Divi’s Laboratories shares gained over 3 per cent as analysts flagged 2026 as a potential inflection point, driven by a ...

Citi said it believes Divi's Laboratories' revenue and earnings before interest, tax, depreciation, and amortisation (EBITDA) ...

Welcome to the Divis Labs Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

Earnings call Divi’s Laboratories reported Q2 FY25 consolidated revenue of ₹2,444 crore, up 22.5% YoY and 11.2% QoQ. Profit after tax rose to ₹510 crore, up 46.6% YoY. Custom synthesis now contributes ...

Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) has shared an announcement. Divi’s Laboratories Limited has announced that it will close its ...

Shares of Divis Laboratories rose 3 percent to Rs 6,188 on Friday, August 22, after global brokerage Citi turned upbeat on the stock, flagging attractive valuations and sector tailwinds. Citi ...

An update from Divi’s Laboratories Limited ( ($IN:DIVISLAB) ) is now available. Divi’s Laboratories Limited has submitted to the National Stock ...

HYDERABAD, Aug 14 (Reuters) - Indian pharmaceutical company Divi's Laboratories (DIVI.NS), opens new tab reported a 49.2% fall in quarterly profit, missing analysts' estimates, as the generic drug ...

Divi's Laboratories has attracted bullish sentiment from leading brokerage houses. The company’s strong fundamentals, robust R&D capabilities, and leadership position in Active Pharmaceutical ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...